|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen JG, White M, Cruz A and
Farias-Eisner R: In 2014, can we do better than CA125 in the early
detection of ovarian cancer? World J Biol Chem. 5:286–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGuire WP, Hoskins WJ, Brady MF, et al:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levy DE and Darnell JE Jr: Stats:
transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng
KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and
cell proliferation in non-small cell lung cancer cells. Am J
Physiol Lung Cell Mol Physiol. 289:L446–L453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robinson DR, Wu YM and Lin SF: The protein
tyrosine kinase family of the human genome. Oncogene. 19:5548–5557.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohashi K, Mizuno K, Kuma K, Miyata T and
Nakamura T: Cloning of the cDNA for a novel receptor tyrosine
kinase, Sky, predominantly expressed in brain. Oncogene. 9:699–705.
1994.PubMed/NCBI
|
|
8
|
Sasaki T, Knyazev PG, Clout NJ, et al:
Structural basis for Gas6-Axl signalling. EMBO J. 25:80–87. 2006.
View Article : Google Scholar
|
|
9
|
Stitt TN, Conn G, Gore M, et al: The
anticoagulation factor protein S and its relative, Gas6, are
ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Cell. 80:661–670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hafizi S and Dahlback B: Gas6 and protein
S: Vitamin K-dependent ligands for the Axl receptor tyrosine kinase
subfamily. FEBS J. 273:5231–5244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ
and Hung MC: Expression profile of tyrosine kinases in breast
cancer. Clin Cancer Res. 8:361–367. 2002.PubMed/NCBI
|
|
12
|
Craven RJ, Xu LH, Weiner TM, et al:
Receptor tyrosine kinases expressed in metastatic colon cancer. Int
J Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu CW, Li AF, Chi CW, et al: Clinical
significance of AXL kinase family in gastric cancer. Anticancer
Res. 22:1071–1078. 2002.PubMed/NCBI
|
|
14
|
Challier C, Uphoff CC, Janssen JW and
Drexler HG: Differential expression of the ufo/axl oncogene in
human leukemia-lymphoma cell lines. Leukemia. 10:781–787.
1996.PubMed/NCBI
|
|
15
|
Gyorffy B and Lage H: A Web-based data
warehouse on gene expression in human malignant melanoma. J Invest
Dermatol. 127:394–399. 2007. View Article : Google Scholar
|
|
16
|
De Vos J, Couderc G, Tarte K, et al:
Identifying intercellular signaling genes expressed in malignant
plasma cells by using complementary DNA arrays. Blood. 98:771–780.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Macleod K, Mullen P, Sewell J, et al:
Altered ErbB receptor signaling and gene expression in
cisplatin-resistant ovarian cancer. Cancer Res. 65:6789–6800. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar
|
|
19
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention: flavonoids and isoflavonoids.
Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manach C, Scalbert A, Morand C, Remesy C
and Jimenez L: Polyphenols: food sources and bioavailability. Am J
Clin Nutr. 79:727–747. 2004.PubMed/NCBI
|
|
22
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng PW, Chiang LC and Lin CC: Apigenin
induced apoptosis through p53-dependent pathway in human cervical
carcinoma cells. Life Sci. 76:1367–1379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu HF, Chie YJ, Yang MS, et al: Apigenin
induces apoptosis in human lung cancer H460 cells through caspase-
and mitochondria-dependent pathways. Hum Exp Toxicol. 30:1053–1061.
2011. View Article : Google Scholar
|
|
25
|
Zhong Y, Krisanapun C, Lee SH, et al:
Molecular targets of apigenin in colorectal cancer cells:
involvement of p21, NAG-1 and p53. Eur J Cancer. 46:3365–3374.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ruela-de-Sousa RR, Fuhler GM, Blom N,
Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of
apigenin on leukemia cell lines: implications for prevention and
therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li ZD, Hu XW, Wang YT and Fang J: Apigenin
inhibits proliferation of ovarian cancer A2780 cells through Id1.
FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mirzoeva S, Kim ND, Chiu K, Franzen CA,
Bergan RC and Pelling JC: Inhibition of HIF-1 alpha and VEGF
expression by the chemopreventive bioflavonoid apigenin is
accompanied by Akt inhibition in human prostate carcinoma PC3-M
cells. Mol Carcinog. 47:686–700. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barre B, Vigneron A, Perkins N, Roninson
IB, Gamelin E and Coqueret O: The STAT3 oncogene as a predictive
marker of drug resistance. Trends Mol Med. 13:4–11. 2007.
View Article : Google Scholar
|
|
30
|
McGuire WP III: Current status of taxane
and platinum-based chemotherapy in ovarian cancer. J Clin Oncol.
21(Suppl 10): 133–135. 2003. View Article : Google Scholar
|
|
31
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ozols RF: Systemic therapy for ovarian
cancer: current status and new treatments. Semin Oncol. 33:S3–S11.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian C, Ambrosone CB, Darcy KM, et al:
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical
outcomes among women with advanced stage ovarian cancer treated
with platinum and taxane-based chemotherapy: a Gynecologic Oncology
Group study. Gynecol Oncol. 124:575–581. 2012. View Article : Google Scholar :
|
|
34
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, et al: Constitutive activation of Stat3 signaling confers
resistance to apoptosis in human U266 myeloma cells. Immunity.
10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pu YS, Hour TC, Chuang SE, Cheng AL, Lai
MK and Kuo ML: Interleukin-6 is responsible for drug resistance and
anti-apoptotic effects in prostatic cancer cells. Prostate.
60:120–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Conze D, Weiss L, Regen PS, et al:
Autocrine production of interleukin 6 causes multidrug resistance
in breast cancer cells. Cancer Res. 61:8851–8858. 2001.PubMed/NCBI
|
|
37
|
Wimmel A, Glitz D, Kraus A, Roeder J and
Schuermann M: Axl receptor tyrosine kinase expression in human lung
cancer cell lines correlates with cellular adhesion. Eur J Cancer.
37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Linger RM, Keating AK, Earp HS and Graham
DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel
therapeutic targets in solid tumors. Expert Opin Ther Targets.
14:1073–1090. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ye X, Li Y, Stawicki S, et al: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Birt DF, Walker B, Tibbels MG and Bresnick
E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and
indole-3-carbinol. Carcinogenesis. 7:959–963. 1986. View Article : Google Scholar : PubMed/NCBI
|
